20/20 Biolabs Reports Nasdaq Listing Compliance Notices

What Happened

• 20/20 Biolabs, Inc. (AIDX) filed an 8-K disclosing Nasdaq notifications that it is not in compliance with the $1.00 bid price requirement and the $2,500,000 stockholders’ equity requirement.
• On July 17, 2026 Nasdaq notified the company that its common stock closed below $1.00 for 30 consecutive business days (June 3–July 16, 2026); Nasdaq granted a 180-calendar-day cure period (until January 13, 2027) to achieve a $1.00 closing bid for at least ten consecutive business days.
• On September 3, 2026 Nasdaq notified the company that its Form 10-Q for the period ended June 30, 2026 reported stockholders’ equity of $1,620,700, below the $2,500,000 minimum; the company has 45 days to submit a plan to regain compliance, and Nasdaq may grant up to 180 days if the plan is accepted.

Key Details

• Bid price rule: $1.00 minimum closing bid; cure requires ≥10 consecutive business days at $1.00+ within 180 days (deadline Jan 13, 2027).
• Equity rule: $2,500,000 minimum stockholders’ equity; reported equity $1,620,700 as of June 30, 2026.
• Timelines: July 17, 2026 (bid-price notice); September 3, 2026 (equity notice); 45 days from Sept. 3 to submit a compliance plan; possible 180-day extension if plan accepted.
• If equity is not regained by Jan 13, 2027, the company will not qualify for a second 180-day extension to cure the bid-price deficiency.

Why It Matters

• These notices put 20/20 Biolabs at risk of Nasdaq delisting if it cannot meet the bid price and equity standards within the deadlines. Delisting would likely reduce liquidity and could make trading and capital raising more difficult.
• The company says it will monitor the stock price and may consider options to regain compliance, and it believes its plan can restore equity compliance, but Nasdaq acceptance is not guaranteed. Investors should watch the company’s corrective actions and any further Nasdaq communications.